Medullary thyroid cancer (MTC) is a distinct C-cell tumor of the thyroid. We review the oncogenesis and management of both sporadic tumors and those tumors arising as part of specific inherited syndromes. The RET proto-oncogene plays a role in the development of inherited forms of MTC and has become important in the clinical management of patients and their families. The recognition of the high rate of regional nodal involvement has led to lymphadenectomy being strongly considered for patients undergoing thyroidectomy for MTC.
References
1.
HundahlS.A., FlemingI.D., FremgenA.M.A National Cancer Data Base report of 53,856 cases of thyroid carcinomas treated in the U.S. 1985–1995. Cancer.1998; 83: 2638–2648.
HazardJ.B., HawkW.A., CrileG.Jr. Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab.1959; 19: 152–161.
4.
SteinerA.L., GoodmanA.D., PowersS.R.Study of kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia type 2. Medicine (Baltimore)1968; 47: 371–409.
5.
EngC.Seminars in medicine of the Beth Israel Hospital, Boston: the RET proto-oncogene in medullary endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med.1996; 335: 943–951.
6.
GagelR.F., CoteG.Decision making in MEN type II. In: MazzaferriE.L., BarR.S., KreisbergR.A., eds. Advances in Endocrinology and Metabolism. Vol 5. St. Louis, Mo: Mosby-Year Book; 1994: 1–23.
7.
ChongG.C., BeahrsO.H., SizemoreG.W.Medullary carcinoma of the thyroid gland. Cancer.1975; 35: 695–704.
8.
O'RiordainD.S., O'BrienT., CrottyT.B.Multiple endocrine neoplasia type 2b: more than an endocrine disorder. Surgery.1995; 118: 936–942.
9.
FarndonJ.R., LeightG.S., DilleyW.G.Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg.1986; 73: 278–281.
10.
OlsonJ.E., HughesJ., AlpernH.D.Family members of patients with sporadic medullary thyroid carcinoma must be screened for hereditary disease. Surgery.1992; 112: 1074–1079.
11.
SaadM.F., OrdonezN.G., RashidR.K.Medullary carcinoma of the thyroid: a study of the clinical features and prognostic factors in 161 patients. Medicine.1984; 63: 319–342.
KnudsonA.G.Jr, StrongL.C., AndersonD.E.Heredity and cancer in man. Prog Med Genet.1973; 9: 113–158.
14.
EngC., MulliganL.M., SmithD.P.Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer.1995; 12: 209–212.
15.
GagelR.F., CoteG.J., Martins BugalhoM.J.Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med.1995; 238: 333–341.
16.
MulliganL.M., KwokJ.B., HealeyC.S.Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature.1993, 363: 458–460.
17.
Donis-KellerH., DouS., ChiD.Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet.1993; 2: 851–856.
18.
LandsvaterR.M., JansenR.P., HofstraR.M.Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B, and FMTC: two novel mutations and one de novo mutation for MEN 2A. Hum Genet.1996; 97: 11–14.
19.
JingS., WenD., YuY.GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha novel receptor for GDNF. Cell.1996; 85: 1113–1124.
20.
MulliganL.M., PonderB.A.Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab.1995; 80: 1989–1995.
21.
LloydR.V.RET proto-oncogene mutations and rearrangements in endocrine diseases. Am J Pathol.1995; 147: 1539–1544.
22.
SantoroM., CarlomagnoF., RomanoA.Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science.1995; 267: 381–383.
23.
TakahashiM.Oncogenic activation of the ret protooncogene in thyroid cancer. Crit Rev Oncog.1995; 6: 35–46.
24.
KomminothP.The RET proto-oncogene in medullary and papillary thyroid carcinoma. Virchows Arch.1997; 431: 1–9.
25.
DeckerR.A., PeacockM.L., BorstM.J.Progress in genetic screening of multiple endocrine neoplasia type 2A. is calcitonin testing obsolete?Surgery.1995; 118: 257–264.
26.
LipsC.J., LandsvaterR.M., HoppenerJ.W.Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia Type 2A. N Engl J Med.1994; 331: 828–835.
27.
PaciniF., RomeiC., MiccoliP.Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery.1995; 118: 1031–1035.
28.
LipsC.J., LandsvaterR.M., HoppenerJ.W.From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family. J Intern Med.1995; 238: 347–356.
29.
O'RiordainD.S., O'BrienT., WeaverA.L.Medullary thyroid carcinoma in multiple endocrine neoplasia type 2A and 2B. Surgery.1994; 116: 1017–1023.
30.
WellsS.A.Jr, ChiD.D., ToshimaK.Predictive DNA testing in prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg.1994; 220: 237–250.
31.
KomminothP., KunzE., Matias-GuiuX.Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer.1995; 76: 479–489.
32.
EngC., MulliganL.M., SmithD.P.Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol.1995; 43: 123–127.
33.
van HeurnL.W., SchaapC., SieG.Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg.1999; 34: 568–571.
34.
DralleH., GimmO., SimonD.Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg.1998; 22: 744–751.
35.
EngC., ClaytonD., SchuffeneckerI.The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET mutation consortium analysis. JAMA.1996; 276: 1575–1579.
36.
GrauerA., RaueF., GagelR.F.Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma. Endocrinol Metab Clin North Am.1990; 19: 613–635.
BergholmU., AdamiH.O., BergstromR.Clinical characteristics in sporadic and familial medullary thyroid carcinoma: a nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer.1989; 63: 1196–1204.
39.
KakudoK., CarneyJ.R., SizemoreG.W.Medullary carcinoma of thyroid: biologic behavior of the sporadic and familial neoplasm. Cancer.1985; 55: 2818–2821.
40.
NiccoliP., Wion-BarbotN., CaronP.Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab.1997; 82: 338–341.
41.
SamaanN.A., HickeyR.C.Medullary carcinoma of the thyroid: differentiating the types and current management. Oncology (Huntingt).1987; 1: 21–28.
42.
van HeerdenJ.A., GrantC.S., GharibH.Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg.1990; 212: 395–41.
SamaanN.A., SchultzP.N., HickeyR.C.Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab.1988; 67: 801–805.
45.
NguyenT.D., ChassardJ.L., LagardeP.Results of postoperative radiation therapy treatment in medullary carcinoma of the thyroid: a retrospective study by the French Federation of Cancer Institutes. The Radiotherapy Cooperative Group. Radiother Oncol.1992; 23: 1–5.
46.
WellsS.A.Jr, BaylinS.B., LeightG.S.The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg.1982; 195: 595–599.
47.
WellsS.A., BaylinS.B., GannD.S.Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging. Ann Surg.1978; 188: 377–383.
FlemingJ.B., LeeJ.E., BouvertM.Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg.1999; 230: 697–707.
50.
DralleH., ScheumannG.F., ProyeC.The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective European multicentre study. J Intern Med.1995; 238: 357–361.
51.
EllenhornJ.D., ShahJ.P., BrennanM.F.Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery.1993; 114: 1078–1082.
52.
MoleyJ.F., DeBenedettiM.K.Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg.1999; 229: 880–888.
53.
CadyB.In discussion of: Grimm O, Dralle H: reoperation in metastatic medullary thyroid carcinoma: is a tumor stage oriented approach justified?Surgery.1997; 122: 1130–1131.
54.
O'RiordainD.S., O'BrienT., GrantC.S.Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery.1993; 114: 1031–1039.
55.
WuL.T., AverbuchS.D., BallD.W.Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbonize. Cancer.1994; 73: 432–436.
56.
ModiglianiE., CohenR., JoannidisS.Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol.1992; 36: 183–186.
57.
HoefnagalC.A., DelpratC.C., Valdes OlmosR.A.Role of [131I] metaiodobenzylguanidine therapy in medullary thyroid carcinoma. J Nucl Biol Med.1991; 35: 334–336.
58.
BergholmU., BergstromR., EkbomA.Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer.1997; 79: 132–138.
59.
JuweidM., SharkeyR., BehrT.Targeting and initial radioimmunotherapy of medullary thyroid cancer with 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res.1995; 55(23 suppl): 5946s–5951s.
60.
BruntL.M., WellsS.A.Jr. Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin North Am.1987; 67: 263–279.
61.
RougierP., ParmentierC., LaplancheA.Medullary thyroid carcinoma: prognostic factors in treatment. Int J Radiat Oncol Biol Phys.1983; 9: 161–169.
62.
BrierleyJ., TsangR., SimpsonW.J.Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid.1996; 6: 305–310.
63.
TungW.S., VeselyT.M., MoleyJ.F.Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery.1995; 118: 1024–1030.
64.
GautvikK.M., TalleK., HagerB.Early liver metastases in patients with medullary carcinoma of the thyroid gland. Cancer.1989; 63: 175–180.
65.
TisellL.E., DilleyW.G., WellsS.A.Jr. Progression of post operative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery.1996; 119: 34–39.
66.
TisellL.E., HanssonG., JanssonS.Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery.1986, 99: 60–66.
